• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Research should include multiple medicine use

Report: Research should include multiple medicine use

December 9, 2013
CenterWatch Staff

Policy, medical training and clinical practice have failed to adapt to a significant increase in the number of patients taking multiple prescription drugs, according to a new report on taking numerous prescription drugs (polypharmacy) and medicines optimization by The King’s Fund.

Estimates suggest from 1995 to 2010 the number of patients taking 10 or more medicines tripled, reflecting a large increase in the number of people with complex, or several, long-term conditions. This is largely driven by an aging and increasingly frail population, but also by increasing use of multiple interventions. While in the past, polypharmacy often has been seen as something to be avoided, the report shows that taking an evidence-based approach to polypharmacy should improve outcomes for many people.

However, with most research and health systems based on single-disease frameworks, policy, medical training and clinical practice  often have not adapted to provide ‘appropriate polypharmacy’—optimizing the use of multiple medicines and prescribing them according to best evidence. The report suggests for polypharmacy to be used more effectively there must be:

  • better training for doctors in managing complex multi-morbidity and in polypharmacy
  • more research set in the context of using treatments where people have several diseases, rather than selecting subjects who have single conditions
  • national guidelines for multi-morbidity to match those for single conditions
  • improved systems, particularly for GPs, to flag problematic polypharmacy
  • regular reviews of patients’ medication and a willingness to consider stopping medication, particularly in cases of limited life expectancy
  • changes in systems of medical care to move away from increased specialization toward a focus on multi-morbidity.

The report says polypharmacy must be better understood and defined, and accompanied by more engagement with patients to ensure medicines are taken in the way prescribers intend. This may require compromise between prescribers and patients to ensure patients feel confident in what they are taking and situations in which medicines go unused or wasted are avoided.

Integrated care now is widely accepted as the way to care for people living with multiple, complex, long-term conditions. Appropriate polypharmacy, or medicines optimization, similarly must be accepted as one of the ways in which more coordinated care can be delivered.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing